Connect with us

Government

Top Biotech Stocks To Watch In October 2021

These top biotech stocks could stand to gain from the current focus on vaccines.
The post Top Biotech Stocks To Watch In October 2021 appeared first on Stock Market News, Quotes, Charts and Financial Information | StockMarket.com.

Published

on

3 Trending Biotech Stocks For Your October 2021 Watchlist

The broader stock market continues to face concerns about the economy and rising bond yields. As a result, I could see some investors turning toward the top biotech stocks in the market now. For the most part, this would be thanks to the constant attention on the industry throughout the current pandemic. After all, biotech companies are the ones behind the life-saving vaccines we employ across the globe today. While high-growth tech stocks are mostly taking a breather amid a surge in Treasury yields, biotech stocks could present an interesting opportunity for investors.

On that note, the current rollout of vaccine booster shots is well underway. According to White House coronavirus response coordinator Jeff Zients, over 400,000 Americans received booster shots over the weekend. This would continue to highlight the relevance of companies such as Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) now. Adding to that, Pfizer CEO Albert Bourla recently provided an update about living with Covid in the long run. According to Bourla, we could return to normalcy within a year, albeit with annual Covid shots. Given the flu-like nature of the virus, this would not be unheard of.

Not to mention, Pfizer is also currently working on developing an mRNA-based flu vaccine. The likes of which are now undergoing clinical trials. Through the same tech from its coronavirus vaccine, Pfizer seems keen on addressing this long-term global health care issue. Aside from these companies, there are plenty of other biotech firms hard at work in the industry now. With that said, here are three making waves in the stock market today.

Top Biotech Stocks To Watch Right Now

Sanofi

To begin with, we will be taking a look at Sanofi. In brief, it is a French multinational pharmaceutical firm. The company is among the largest pharmaceutical businesses in the world in terms of prescription sales. Regarding its developmental pipeline, Sanofi is currently developing treatments for a wide selection of fields in the health care industry. This includes immunology & inflammation, oncology, rare blood disorders, neurology, and vaccines among other areas. As such, SNY stock could be worth noting among the top biotech stocks now.

If anything, Sanofi appears to be kicking into high gear on the operational front. Yesterday, the company announced positive results from clinical trials of its own mRNA-based Covid vaccine. Namely, data from the studies suggest that Sanofi’s mRNA vaccine development tech is effective and viable. Moving forward, the company is aiming to redirect these findings towards building its mRNA development team against other diseases. According to Global Head of Research at Sanofi, Jean-Francois Toussaint, this will include work on a vaccine flu starting in 2022.

Moreover, the company also provided a notable update on its ongoing partnership with GlaxoSmithKline (NYSE: GSK). The duo are actively working on an adjuvanted recombinant protein candidate vaccine. Sanofi is expanding this study to include research on applications towards broader public health sectors as well. Would all of this make SNY stock a top stock to watch for you?

SNY stock chart
Source: TD Ameritrade TOS

[Read More] What Stocks To Buy Today? 5 Tech Stocks To Watch

Merck & Company

Another name to consider in the biotech stock trade this week would be Merck & Company. Similar to our previous entry, Merck is another multinational pharmaceutical company to know now. Given its extensive experience in developing treatments for over a century, Merck is no newcomer to the biotech game. In fact, it is a leading name in the global biotech industry now. This is evident given its work with diseases such as cancer, HIV, and Ebola. Accordingly, investors could be looking at MRK stock now because of all this.

Despite its current momentum, Merck does not appear to be slowing down anytime soon. For starters, the company announced significantly positive results from clinical trials of its hepatocellular carcinoma (HC) drug, KEYTRUDA. In its Phase 3 study, Merck found that the treatment showed “statistically significant improvement” in the overall survival of patients versus a placebo group. Ideally, this would bring Merck another step closer to market. This would be crucial given that HC has “one of the highest mortality rates” among solid cancers, according to Merck VP of clinical research, Dr. Scot Ebbinghaus. Moving forward, Dr. Ebbinghaus notes that Merck is eager to engage with regulatory authorities soon.

Additionally, news broke yesterday regarding the company’s ongoing talks to acquire Acceleron Pharma (NASDAQ: XLRN). Should things go as planned, Acceleron’s FDA-approved anemia treatment would significantly bolster Merck’s rare disease portfolio. Based on The Wall Street Journal sources, the deal could value Accleron at around $11 billion and could be finalized this week. All things considered, will you be adding MRK stock to your watchlist?

MRK stock chart
Source: TD Ameritrade TOS

[Read More] Top Stocks To Buy Now? 4 Renewable Energy Stocks For Your Watchlist

Sonoma Pharmaceuticals Inc.

Following that, we have Sonoma Pharmaceuticals. In essence, Sonoma is an upcoming player in the global health care industry today. The company is mainly known for its work in developing stabilized hypochlorous acid (HOCl) products. According to Sonoma, said products boast a range of applications. This includes but is not limited to wound care, eye care, nasal & oral care, and disinfectant use. For a sense of scale, Sonoma’s wares are marketed in 54 countries across the globe now.

Thanks to the company’s latest announcement, SNOA stock seems to be gaining traction in the stock market. Evidently, SNOA stock skyrocketed by over 30% during intraday trading yesterday. In detail, Sonoma launched its first over-the-counter products in the U.S. These are its Regenacyn scar gel and Ocucyn eyelid cleanser. Notably, the company is now partnering up with e-commerce giant Amazon (NASDAQ: AMZN) to accomplish this. Furthermore, the company is also launching another product on Amazon sites in Europe as well.

Overall, CEO Amy Trombly had this to say, “We could not be more excited about making our safe and effective products available directly to consumers through Amazon. We look forward to offering our clinically proven and patented Microcyn® Technology to a wider range of patients for advanced scar management, eyelid & eyelash hygiene, and personal protection spray for the face and skin.” With this development, some would argue that SNOA stock could have more room to grow moving forward. Would you agree?

SNOA stock chart
Source: TD Ameritrade TOS

The post Top Biotech Stocks To Watch In October 2021 appeared first on Stock Market News, Quotes, Charts and Financial Information | StockMarket.com.

Read More

Continue Reading

Government

Are Voters Recoiling Against Disorder?

Are Voters Recoiling Against Disorder?

Authored by Michael Barone via The Epoch Times (emphasis ours),

The headlines coming out of the Super…

Published

on

Are Voters Recoiling Against Disorder?

Authored by Michael Barone via The Epoch Times (emphasis ours),

The headlines coming out of the Super Tuesday primaries have got it right. Barring cataclysmic changes, Donald Trump and Joe Biden will be the Republican and Democratic nominees for president in 2024.

(Left) President Joe Biden delivers remarks on canceling student debt at Culver City Julian Dixon Library in Culver City, Calif., on Feb. 21, 2024. (Right) Republican presidential candidate and former U.S. President Donald Trump stands on stage during a campaign event at Big League Dreams Las Vegas in Las Vegas, Nev., on Jan. 27, 2024. (Mario Tama/Getty Images; David Becker/Getty Images)

With Nikki Haley’s withdrawal, there will be no more significantly contested primaries or caucuses—the earliest both parties’ races have been over since something like the current primary-dominated system was put in place in 1972.

The primary results have spotlighted some of both nominees’ weaknesses.

Donald Trump lost high-income, high-educated constituencies, including the entire metro area—aka the Swamp. Many but by no means all Haley votes there were cast by Biden Democrats. Mr. Trump can’t afford to lose too many of the others in target states like Pennsylvania and Michigan.

Majorities and large minorities of voters in overwhelmingly Latino counties in Texas’s Rio Grande Valley and some in Houston voted against Joe Biden, and even more against Senate nominee Rep. Colin Allred (D-Texas).

Returns from Hispanic precincts in New Hampshire and Massachusetts show the same thing. Mr. Biden can’t afford to lose too many Latino votes in target states like Arizona and Georgia.

When Mr. Trump rode down that escalator in 2015, commentators assumed he’d repel Latinos. Instead, Latino voters nationally, and especially the closest eyewitnesses of Biden’s open-border policy, have been trending heavily Republican.

High-income liberal Democrats may sport lawn signs proclaiming, “In this house, we believe ... no human is illegal.” The logical consequence of that belief is an open border. But modest-income folks in border counties know that flows of illegal immigrants result in disorder, disease, and crime.

There is plenty of impatience with increased disorder in election returns below the presidential level. Consider Los Angeles County, America’s largest county, with nearly 10 million people, more people than 40 of the 50 states. It voted 71 percent for Mr. Biden in 2020.

Current returns show county District Attorney George Gascon winning only 21 percent of the vote in the nonpartisan primary. He’ll apparently face Republican Nathan Hochman, a critic of his liberal policies, in November.

Gascon, elected after the May 2020 death of counterfeit-passing suspect George Floyd in Minneapolis, is one of many county prosecutors supported by billionaire George Soros. His policies include not charging juveniles as adults, not seeking higher penalties for gang membership or use of firearms, and bringing fewer misdemeanor cases.

The predictable result has been increased car thefts, burglaries, and personal robberies. Some 120 assistant district attorneys have left the office, and there’s a backlog of 10,000 unprosecuted cases.

More than a dozen other Soros-backed and similarly liberal prosecutors have faced strong opposition or have left office.

St. Louis prosecutor Kim Gardner resigned last May amid lawsuits seeking her removal, Milwaukee’s John Chisholm retired in January, and Baltimore’s Marilyn Mosby was defeated in July 2022 and convicted of perjury in September 2023. Last November, Loudoun County, Virginia, voters (62 percent Biden) ousted liberal Buta Biberaj, who declined to prosecute a transgender student for assault, and in June 2022 voters in San Francisco (85 percent Biden) recalled famed radical Chesa Boudin.

Similarly, this Tuesday, voters in San Francisco passed ballot measures strengthening police powers and requiring treatment of drug-addicted welfare recipients.

In retrospect, it appears the Floyd video, appearing after three months of COVID-19 confinement, sparked a frenzied, even crazed reaction, especially among the highly educated and articulate. One fatal incident was seen as proof that America’s “systemic racism” was worse than ever and that police forces should be defunded and perhaps abolished.

2020 was “the year America went crazy,” I wrote in January 2021, a year in which police funding was actually cut by Democrats in New York, Los Angeles, San Francisco, Seattle, and Denver. A year in which young New York Times (NYT) staffers claimed they were endangered by the publication of Sen. Tom Cotton’s (R-Ark.) opinion article advocating calling in military forces if necessary to stop rioting, as had been done in Detroit in 1967 and Los Angeles in 1992. A craven NYT publisher even fired the editorial page editor for running the article.

Evidence of visible and tangible discontent with increasing violence and its consequences—barren and locked shelves in Manhattan chain drugstores, skyrocketing carjackings in Washington, D.C.—is as unmistakable in polls and election results as it is in daily life in large metropolitan areas. Maybe 2024 will turn out to be the year even liberal America stopped acting crazy.

Chaos and disorder work against incumbents, as they did in 1968 when Democrats saw their party’s popular vote fall from 61 percent to 43 percent.

Views expressed in this article are opinions of the author and do not necessarily reflect the views of The Epoch Times or ZeroHedge.

Tyler Durden Sat, 03/09/2024 - 23:20

Read More

Continue Reading

Government

Veterans Affairs Kept COVID-19 Vaccine Mandate In Place Without Evidence

Veterans Affairs Kept COVID-19 Vaccine Mandate In Place Without Evidence

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

The…

Published

on

Veterans Affairs Kept COVID-19 Vaccine Mandate In Place Without Evidence

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

The U.S. Department of Veterans Affairs (VA) reviewed no data when deciding in 2023 to keep its COVID-19 vaccine mandate in place.

Doses of a COVID-19 vaccine in Washington in a file image. (Jacquelyn Martin/Pool/AFP via Getty Images)

VA Secretary Denis McDonough said on May 1, 2023, that the end of many other federal mandates “will not impact current policies at the Department of Veterans Affairs.”

He said the mandate was remaining for VA health care personnel “to ensure the safety of veterans and our colleagues.”

Mr. McDonough did not cite any studies or other data. A VA spokesperson declined to provide any data that was reviewed when deciding not to rescind the mandate. The Epoch Times submitted a Freedom of Information Act for “all documents outlining which data was relied upon when establishing the mandate when deciding to keep the mandate in place.”

The agency searched for such data and did not find any.

The VA does not even attempt to justify its policies with science, because it can’t,” Leslie Manookian, president and founder of the Health Freedom Defense Fund, told The Epoch Times.

“The VA just trusts that the process and cost of challenging its unfounded policies is so onerous, most people are dissuaded from even trying,” she added.

The VA’s mandate remains in place to this day.

The VA’s website claims that vaccines “help protect you from getting severe illness” and “offer good protection against most COVID-19 variants,” pointing in part to observational data from the U.S. Centers for Disease Control and Prevention (CDC) that estimate the vaccines provide poor protection against symptomatic infection and transient shielding against hospitalization.

There have also been increasing concerns among outside scientists about confirmed side effects like heart inflammation—the VA hid a safety signal it detected for the inflammation—and possible side effects such as tinnitus, which shift the benefit-risk calculus.

President Joe Biden imposed a slate of COVID-19 vaccine mandates in 2021. The VA was the first federal agency to implement a mandate.

President Biden rescinded the mandates in May 2023, citing a drop in COVID-19 cases and hospitalizations. His administration maintains the choice to require vaccines was the right one and saved lives.

“Our administration’s vaccination requirements helped ensure the safety of workers in critical workforces including those in the healthcare and education sectors, protecting themselves and the populations they serve, and strengthening their ability to provide services without disruptions to operations,” the White House said.

Some experts said requiring vaccination meant many younger people were forced to get a vaccine despite the risks potentially outweighing the benefits, leaving fewer doses for older adults.

By mandating the vaccines to younger people and those with natural immunity from having had COVID, older people in the U.S. and other countries did not have access to them, and many people might have died because of that,” Martin Kulldorff, a professor of medicine on leave from Harvard Medical School, told The Epoch Times previously.

The VA was one of just a handful of agencies to keep its mandate in place following the removal of many federal mandates.

“At this time, the vaccine requirement will remain in effect for VA health care personnel, including VA psychologists, pharmacists, social workers, nursing assistants, physical therapists, respiratory therapists, peer specialists, medical support assistants, engineers, housekeepers, and other clinical, administrative, and infrastructure support employees,” Mr. McDonough wrote to VA employees at the time.

This also includes VA volunteers and contractors. Effectively, this means that any Veterans Health Administration (VHA) employee, volunteer, or contractor who works in VHA facilities, visits VHA facilities, or provides direct care to those we serve will still be subject to the vaccine requirement at this time,” he said. “We continue to monitor and discuss this requirement, and we will provide more information about the vaccination requirements for VA health care employees soon. As always, we will process requests for vaccination exceptions in accordance with applicable laws, regulations, and policies.”

The version of the shots cleared in the fall of 2022, and available through the fall of 2023, did not have any clinical trial data supporting them.

A new version was approved in the fall of 2023 because there were indications that the shots not only offered temporary protection but also that the level of protection was lower than what was observed during earlier stages of the pandemic.

Ms. Manookian, whose group has challenged several of the federal mandates, said that the mandate “illustrates the dangers of the administrative state and how these federal agencies have become a law unto themselves.”

Tyler Durden Sat, 03/09/2024 - 22:10

Read More

Continue Reading

Government

Low Iron Levels In Blood Could Trigger Long COVID: Study

Low Iron Levels In Blood Could Trigger Long COVID: Study

Authored by Amie Dahnke via The Epoch Times (emphasis ours),

People with inadequate…

Published

on

Low Iron Levels In Blood Could Trigger Long COVID: Study

Authored by Amie Dahnke via The Epoch Times (emphasis ours),

People with inadequate iron levels in their blood due to a COVID-19 infection could be at greater risk of long COVID.

(Shutterstock)

A new study indicates that problems with iron levels in the bloodstream likely trigger chronic inflammation and other conditions associated with the post-COVID phenomenon. The findings, published on March 1 in Nature Immunology, could offer new ways to treat or prevent the condition.

Long COVID Patients Have Low Iron Levels

Researchers at the University of Cambridge pinpointed low iron as a potential link to long-COVID symptoms thanks to a study they initiated shortly after the start of the pandemic. They recruited people who tested positive for the virus to provide blood samples for analysis over a year, which allowed the researchers to look for post-infection changes in the blood. The researchers looked at 214 samples and found that 45 percent of patients reported symptoms of long COVID that lasted between three and 10 months.

In analyzing the blood samples, the research team noticed that people experiencing long COVID had low iron levels, contributing to anemia and low red blood cell production, just two weeks after they were diagnosed with COVID-19. This was true for patients regardless of age, sex, or the initial severity of their infection.

According to one of the study co-authors, the removal of iron from the bloodstream is a natural process and defense mechanism of the body.

But it can jeopardize a person’s recovery.

When the body has an infection, it responds by removing iron from the bloodstream. This protects us from potentially lethal bacteria that capture the iron in the bloodstream and grow rapidly. It’s an evolutionary response that redistributes iron in the body, and the blood plasma becomes an iron desert,” University of Oxford professor Hal Drakesmith said in a press release. “However, if this goes on for a long time, there is less iron for red blood cells, so oxygen is transported less efficiently affecting metabolism and energy production, and for white blood cells, which need iron to work properly. The protective mechanism ends up becoming a problem.”

The research team believes that consistently low iron levels could explain why individuals with long COVID continue to experience fatigue and difficulty exercising. As such, the researchers suggested iron supplementation to help regulate and prevent the often debilitating symptoms associated with long COVID.

It isn’t necessarily the case that individuals don’t have enough iron in their body, it’s just that it’s trapped in the wrong place,” Aimee Hanson, a postdoctoral researcher at the University of Cambridge who worked on the study, said in the press release. “What we need is a way to remobilize the iron and pull it back into the bloodstream, where it becomes more useful to the red blood cells.”

The research team pointed out that iron supplementation isn’t always straightforward. Achieving the right level of iron varies from person to person. Too much iron can cause stomach issues, ranging from constipation, nausea, and abdominal pain to gastritis and gastric lesions.

1 in 5 Still Affected by Long COVID

COVID-19 has affected nearly 40 percent of Americans, with one in five of those still suffering from symptoms of long COVID, according to the U.S. Centers for Disease Control and Prevention (CDC). Long COVID is marked by health issues that continue at least four weeks after an individual was initially diagnosed with COVID-19. Symptoms can last for days, weeks, months, or years and may include fatigue, cough or chest pain, headache, brain fog, depression or anxiety, digestive issues, and joint or muscle pain.

Tyler Durden Sat, 03/09/2024 - 12:50

Read More

Continue Reading

Trending